Rapport Therapeutics, Inc. (RAPP)
| Market Cap | 1.47B +17.8% |
| Revenue (ttm) | 20.00M |
| Net Income | -137.16M |
| EPS | -3.05 |
| Shares Out | 47.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 247,879 |
| Open | 29.73 |
| Previous Close | 29.85 |
| Day's Range | 29.50 - 31.20 |
| 52-Week Range | 23.75 - 52.93 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 63.04 (+105.68%) |
| Est. Earnings | Nov 5, 2026 |
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorde... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price target is $63.04, which is an increase of 105.68% from the latest price.
News
Guggenheim starts Rapport Therapeutics at Buy on ‘de-risked’ Phase 2a study
As previously reported, Guggenheim initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $65 price target The firm is citing de-risked Phase 3 prospects for the company’s lead…
Rapport Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $65 price target
Rapport drops after CEO presents at TD Cowen Neuropsychiatry Summit
Shares of Rapport Therapeutics (RAPP) were dropping after the company presented at TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit. Of note, CEO Abe Cassey said that he would…
Rapport Therapeutics Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
RAP-219 is advancing in both epilepsy and bipolar mania, leveraging a precision neuroscience approach and targeting significant unmet needs with a differentiated tolerability profile. The bipolar mania program is positioned for pivotal trials, with a strong financial runway and plans for both oral and long-acting injectable formulations.
Rapport Therapeutics Transcript: KOL event
Experts discussed the high unmet need in bipolar mania, emphasizing RAP-219’s novel, targeted mechanism and robust trial design aimed at improving efficacy and tolerability. The phase II trial leverages strict inclusion criteria and advanced analytics, with a positive result potentially expanding the market and offering a differentiated treatment option.
Rapport Therapeutics Slides: KOL event
Rapport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 22, 2026.
Rapport Therapeutics price target raised to $75 from $65 at BTIG
BTIG analyst Kambiz Yazdi raised the firm’s price target on Rapport Therapeutics (RAPP) to $75 from $65 and keeps a Buy rating on the shares. The firm is citing its…
Rapport Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted a precision neuroscience pipeline with RAP-219 advancing in both bipolar mania and focal onset seizures, showing strong efficacy and safety. A long-acting injectable is in development, potentially doubling market opportunity and extending exclusivity.
Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and d...
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Rapport Therapeutics price target raised to $75 from $68 at Raymond James
Raymond James analyst Tiago Fauth raised the firm’s price target on Rapport Therapeutics (RAPP) to $75 from $68 and keeps a Strong Buy rating on the shares. Rapport’s RAP-219 bipolar…
Rapport Therapeutics price target raised to $66 from $40 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Rapport Therapeutics (RAPP) to $66 from $40 and keeps a Buy rating on the shares after speaking with management.
Rapport Therapeutics reports Q2 EPS ($1.19), consensus (99c)
“We remain focused on disciplined execution as we deliver against several important catalysts this year,” said Abraham N. Ceesay, chief executive officer of Rapport. “With FOCUS 1 and FOCUS 2…
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeli...
Rapport Therapeutics Earnings release: Q2 2026
Rapport Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Rapport Therapeutics Quarterly report: Q2 2026
Rapport Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Rapport Therapeutics Slides: Corporate presentation
Rapport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Rapport Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $79.03 fair value estimate. Rapport is a clinical-stage leader in developing therapies targeting receptor-...
Rapport Therapeutics management to meet with Citizens
Meeting to be held in Boston on July 21 hosted by Citizens.
Rapport Therapeutics Slides: Corporate presentation
Rapport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Rapport Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $52 price target The epilepsy market is attractive due to efficient drug development, predictable translation fr...
Rapport Therapeutics management to meet with Citizens
Meeting to be held in Boston on June 23 hosted by Citizens.
Rapport Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with the election of three directors and the ratification of the audit firm, both of which were approved by stockholders. No additional nominations or questions were received, and all proposals passed as recommended.
Rapport Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Phase III trials for RAP-219 in focal-onset seizures are enrolling globally, supported by strong phase II data and a China partnership to accelerate recruitment. The pipeline includes upcoming trials in bipolar mania, primary generalized tonic-clonic seizures, and pain, with a cash runway into 2029.
Rapport Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
RAP-219, a precision neuroscience asset, is advancing through phase III trials for focal epilepsy, with strong phase II efficacy and a robust safety focus. A long-acting injectable is in development, and pivotal data for bipolar mania and open label extension are expected in Q4.